OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered
and developed by OSI to obtain FDA approval and the only EGFR inhibitor to
have demonstrated the ability to improve survival in both non-small cell lung
cancer and pancreatic cancer patients. PRP's lead products
under development are InsuLAR(TM), a once-a-week basal insulin injection and
PulmoLAR(TM), a sustained release preparation for the treatment of Pulmonary
Arterial Hypertension. As a result, Tesma will become a wholly-owned subsidiary of
Magna.
Tesma, a global supplier of highly-engineered engine, transmission and
fuel system components, modules and systems for the automotive industry,
employs over 5,800 skilled and motivated people in 28 manufacturing facilities
in North and South America, Europe and Asia, and five focused tooling, design
and R+D centres supporting its three principal product technology groups:
Tesma Engine Technologies; Tesma Transmission Technologies; and Tesma Fuel
Technologies .

sohu splice

PRP collaborates with other pharmaceutical companies who desire to enhance
the benefits of their proprietary molecules through PRP's sustained release
technologies.

Please submit your URL to another category.

silicom nasdaq

, PR Pharmaceuticals, Inc. "Dosing
convenience is important for retina specialists and patients who are fighting
age-related blindness. VEGF is a protein that plays a critical role in angiogenesis (the
formation of new blood vessels) and increased permeability (leakage from blood
vessels), two pathological processes that contribute to the vision loss
associated with neovascular AMD. and with Roche throughout the
rest of the world. Macugen(R) (pegaptanib sodium injection) is approved in
the United States for the treatment of neovascular age-related macular
degeneration .5672 per
share for Tesma shareholders who made cash elections.

sji sbe

AURORA, ON, Feb.SV.m.

stolt commercializes

;
various engine, transmission and fueling systems and components through Tesma
International Inc.

vidmar ipec

macugen. (OSI) Prosidion is committed to the generation of
novel, targeted therapies for the treatment of type 2 diabetes and obesity. 4 - Magna International Inc.

svb nyse

PR Pharmaceuticals (PRP) Announces Collaboration With OSI Pharmaceuticals to Develop Sustained Release Formulation of Macugen(R) (pegaptanib sodium injection)

Serious adverse events related to the injection procedure occurring in <1%
of intravitreal injections included endophthalmitis, retinal detachment, and
iatrogenic traumatic cataract. These events occurred in approximately 10% to 40% of patients.SV.A, MG.B, NYSE: MGA) ("Magna ") and Tesma International Inc. Otherwise, Tesma
shareholders will receive 0.

syncor sungard

PRP is a Fort Collins, CO based privately held Biopharmaceutical Company. In consideration for Magna's acquisition of all of the issued and
outstanding Class A Subordinate Voting shares of Tesma not already owned by
it, Magna will issue 6,687,709 Class A Subordinate Voting shares in exchange
for Tesma Class A Subordinate Voting shares and pay approximately
Cdn.
Magna has approximately 81,000 employees in 219 manufacturing operations and
49 product development and engineering centres in 22 countries .

nasdaq splice

Proper aseptic injection technique -- which includes
use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or
equivalent) -- should always be utilized when administering Macugen . The Company operates
through three business teams, (OSI) Oncology, (OSI) Eyetech and (OSI)
Prosidion . For
additional information about OSI, please visit http://www.$127,695,000 to Tesma shareholders who made cash elections and for
fractional shares.

syncor staar

Increases in intraocular pressure (IOP ) have been seen within 30 minutes
of injection with Macugen.com.

This category is being disbanded .

syms superconductor

Macugen is a
pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor
(VEGF).osip. For purposes of the cash elections, the volume-weighted
average trading price of Magna 's Class A Subordinate Voting shares on the
Toronto Stock Exchange ("TSX") over the five trading days ended February 4,
2005 was Cdn.$94.$41.

nasdaq silicom

OSI, through its eye disease unit (OSI) Eyetech, is responsible for
clinical development activities and has the right to manufacture and
commercialize any resulting product.
For full prescribing information about Macugen, please visit
http://www. (OSI) Oncology is focused on developing molecular targeted
therapies designed to change the paradigm of cancer care . OSI commercializes Macugen in partnership with Pfizer Inc.
The company has unique sustained release injectable technologies and uses
these primarily to develop its own proprietary products.

sohu splice

Under the terms of the collaboration, PRP grants OSI Pharmaceuticals an
exclusive license to use PRP's ProPhase(TM) technology with respect to Macugen
in the treatment of eye diseases.
Intravitreal injections including those with Macugen have been associated
with endophthalmitis.

About PR Pharmaceuticals, Inc. on
February 6, 2005.

commercializes ipec

About Macugen
Macugen is indicated in the United States for the treatment of neovascular
age-related macular degeneration (neovascular AMD) and is administered in a
0. In
addition, patients should be monitored during the week following the injection
to permit early treatment, should an infection occur.prpharm.4709 per share, resulting in a payment of Cdn. Magna's products include: automotive
interior and closure components, systems and modules through Intier Automotive
Inc.

spw ipec

; metal body systems, components, assemblies and modules through Cosma
International; exterior and interior mirror and engineered glass systems
through Magna Donnelly; fascias, front and rear end modules, plastic body
panels, exterior trim components and systems, greenhouse and sealing systems,
roof modules and lighting components through Decoma International Inc.

syms silicom

"We are proud to
partner with OSI.

Joint press release - Tesma privatization completed

vidmar silicom

"This collaboration brings together the scientific and technical expertise
to develop a sustained release formulation of Macugen, our breakthrough
medicine for neovascular AMD," said David Guyer, M.

About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicines and changing lives"
by discovering, developing and commercializing high-quality and novel
pharmaceutical products that extend life or improve the quality of life for
patients with cancer , eye diseases, and diabetes. OSI markets Tarceva through
partnerships with Genentech, Inc.
Magna, the most diversified automotive supplier in the world, designs,
develops and manufactures automotive systems, assemblies, modules and
components, and engineers and assembles complete vehicles , primarily for sale
to original equipment manufacturers of cars and light trucks in North America ,
Europe, Mexico, South America and Asia.

commercializes sonera

announced today an exclusive agreement with OSI Pharmaceuticals to collaborate
on the development of a sustained release formulation of Macugen(R)
(pegaptanib sodium injection), a novel treatment for neovascular age-related
macular degeneration (neovascular AMD), using PRP's proprietary ProPhase(TM)
encapsulation technology., chief executive officer
of (OSI) Eyetech and executive vice president of OSI Pharmaceuticals.

stolt vidmar

D.

Important Safety Information
Macugen is contraindicated in patients with ocular or periocular
infections.44 of a Magna Class A Subordinate Voting Share for
each Tesma Class A Subordinate Voting share under the arrangement .

commercializes systemone

PRP is responsible for developing the
formulations and manufacturing the test article for non-clinical and clinical
trials."
PRP received an undisclosed upfront payment from (OSI) Eyetech and also
will receive payments for achieving certain milestones and royalties on net
sales of any products resulting from the collaboration. OSI will reimburse
PRP for efforts carried out by PRP in support of the collaboration.S.
(TSX: MG.
(TSX: TSM.

spw silicom

The agreement gives OSI and its development
and marketing partner Pfizer access to a proprietary method for encapsulating
Macugen for use in ophthalmology ."
"For PRP, this agreement demonstrates the value of our broad intellectual
property estate and expertise in the formulation of sustained release large
molecules," said Steve Howe, chief executive officer of PRP.3-mg dose once every six weeks by intravitreal injection. (OSI) Eyetech
specializes in the development and commercialization of novel therapeutics to
treat diseases of the eye.

svb systemone

Collaboration Aims to Improve Dosing Convenience for Patients Treated for
Neovascular Age-Related Macular Degeneration (neovascular AMD)

FORT COLLINS, Colo.com.

spw superconductor

MV.

nasdaq sohu

Therefore, IOP as well as the perfusion of the
optic nerve head should be monitored and managed appropriately. More information about PRP on our website http://www.

Thanks
ODP Editors

splice svb

Most frequently reported adverse events in patients treated for up to two
years were anterior chamber inflammation, blurred vision , cataract,
conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye
pain, hypertension , increased IOP, ocular discomfort, punctate keratitis,
reduced visual acuity, visual disturbance , vitreous floaters, and vitreous
opacities. in the U.com

A; NASDAQ: TSMA) ("Tesma") today jointly announced that Magna's
privatization of Tesma by way of a plan of arrangement under Ontario law,
which received shareholder approval on February 1, 2005 and final court
approval on February 3, 2005, will become effective at 12:01 a.; a variety of drivetrain components through Magna
Drivetrain; and complete vehicle engineering and assembly through Magna Steyr.

sji superconductor

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)